Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, headquartered in Great Britain, is a leading biopharmaceutical company dedicated to developing innovative treatments for patients with serious conditions. Founded in 2003, Jazz has made significant strides in the industry, particularly in the areas of sleep medicine and neurology. The company’s core products, including Xyrem and Sunosi, are renowned for their unique formulations that address complex health issues such as narcolepsy and excessive daytime sleepiness. With a strong market position, Jazz Pharmaceuticals has achieved notable milestones, including strategic acquisitions that have expanded its therapeutic portfolio and global reach. Operating primarily in North America and Europe, Jazz Pharmaceuticals continues to focus on delivering high-quality, patient-centric solutions that enhance the quality of life for individuals facing challenging health conditions.
DitchCarbon Score
How does Jazz Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jazz Pharmaceuticals's score of 3 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Jazz Pharmaceuticals's reported carbon emissions
Jazz Pharmaceuticals, headquartered in Great Britain, currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of data suggests that the company may still be in the early stages of formalising its climate commitments or reporting on its environmental impact. As the pharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Jazz Pharmaceuticals to establish clear emissions reduction strategies and transparent reporting practices to align with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jazz Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
